NUTMEG: A randomised phase II study of nivolumab and temozolomide (TMZ) versus TMZ alone in elderly patients with newly diagnosed glioblastoma (GBM): Trial in progress
conference contribution
posted on 2018-11-01, 00:00authored byMustafa Khasraw, Kerrie L McDonald, Sonia Yip, Roel Verhaak, Amy Heimberger, Merryn Hall, Lauren Fisher, Elizabeth Barnes, Mark Rosenthal, Craig Gedye, Elizabeth Hovey, Benjamin M Ellingson, John Simes, Annette Tongela, Helen Wheeler, Eng-Siew Koh, Hui Gan, Michael Back, Zarnie Lwin
NUTMEG: A randomised phase II study of nivolumab and temozolomide (TMZ) versus TMZ alone in elderly patients with newly diagnosed glioblastoma (GBM): Trial in progress